Eli Lilly vs Novo Nordisk (LLY vs NVO)
Novo Nordisk trades at 10.0x earnings vs 44.9x for Eli Lilly; Eli Lilly grows sales faster (+38.6% vs +5.6%). Margins, debt and dividend, Nov 2026.
Quick answer
On today's data (November 19, 2026): Novo Nordisk looks cheaper on P/E: 10.0x against 44.9x for Eli Lilly. Eli Lilly grows faster: sales +38.6% against +5.6% for Novo Nordisk in the latest quarter. Novo Nordisk has the better net margin: 33.9% against 31.9% for Eli Lilly.
This is a snapshot of the numbers, not a recommendation to buy or sell.
Your first analysis is free with a free account, no card.
Short answer
On P/E as of November 19, 2026, Eli Lilly is the more expensive of the two: it trades at 44.9x its annual earnings against 10.0x for Novo Nordisk. Eli Lilly sells prescription medicines. Its largest revenue source is tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, followed by Verzenio for breast cancer, Jardiance and Trulicity for diabetes, Taltz for immunology and Kisunla for Alzheimer's disease. Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. What helps read that gap: Eli Lilly sales +38.6% against +5.6% for Novo Nordisk in the latest quarter; net margin 31.9% against 33.9%; net debt for Eli Lilly: 1.0x EBITDA against 0.5x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.
Eli Lilly (LLY) and Novo Nordisk (NVO) compete in healthcare and pharma. Here are Eli Lilly and Novo Nordisk side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Eli Lilly or Novo Nordisk.
Eli Lilly vs Novo Nordisk: the figures
| Figure | Eli Lilly | Novo Nordisk |
|---|---|---|
| Share price | $1,382.75 (November 18, 2026) | $39.43 (November 18, 2026) |
| Market cap | $1.23 trillion | $173.8 billion |
| P/E (TTM) | 44.9x | 10.0x |
| Forward P/E | 27.2x | 1.7x |
| Revenue growth (quarter) | +38.6% | +5.6% |
| Net margin (TTM) | 31.9% | 33.9% |
| Net debt / EBITDA | 1.0x | 0.5x |
| Dividend yield | 0.50% | 4.56% |
| Beta | 0.39 | 0.37 |
Eli Lilly and Novo Nordisk figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Eli Lilly or Novo Nordisk figure is not available, and we never estimate it.
3 key differences between Eli Lilly and Novo Nordisk
- Valuation: Eli Lilly trades at 44.9x its annual earnings and Novo Nordisk at 10.0x; the market pays more for each dollar of Eli Lilly profit, usually because it expects more growth.
- Growth: Eli Lilly grew sales +38.6% year on year in its latest quarter, against +5.6% for Novo Nordisk.
- Dividend: Novo Nordisk yields 4.56% at today's price and Eli Lilly yields 0.50%.
Eli Lilly or Novo Nordisk: which fits your profile
- If you want growth: Eli Lilly is growing faster today, with sales +38.6% against +5.6% for Novo Nordisk and also trades on a higher P/E (44.9x against 10.0x). Investors who prioritise growth usually accept more volatility; the P/E only shows what you pay today for each unit of the last 12 months' earnings.
- If you want income (dividends): Novo Nordisk pays the higher dividend relative to its price.
- If you prefer caution: Novo Nordisk has less debt relative to its profit, which usually gives more room in a bad year.
- If price is what matters most to you: Novo Nordisk trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.
Neither Eli Lilly nor Novo Nordisk wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
Verdict: Eli Lilly or Novo Nordisk?
Of the 6 comparable figures in the table, Eli Lilly stands out on 1 (sales growth) and Novo Nordisk stands out on 5 (net margin, lower P/E, dividend yield, less debt over EBITDA and lower volatility (beta)). That does not name a winner between Eli Lilly and Novo Nordisk: the table is a snapshot of today, not a forecast.
Keep reading free.
Create your free account to continue reading “Eli Lilly vs Novo Nordisk (LLY vs NVO)”.
No card required
Eli Lilly vs Novo Nordisk by dimension
Strategy
Eli Lilly operates in healthcare and pharma and Novo Nordisk in healthcare and pharma, so they only fight for the same customer when the sector overlaps. By stock-market size, Eli Lilly is the larger of the two.
Products and AI
Eli Lilly and Novo Nordisk sell different things: Eli Lilly sells prescription medicines. And for Novo Nordisk: Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders.
Margins
Novo Nordisk is more profitable: it keeps 33.9 of every 100 it sells, against 31.9 for Eli Lilly.
Valuation
Eli Lilly trades at the higher P/E (44.9x against 10.0x for Novo Nordisk). A higher P/E is only justified if earnings grow faster.
Risks
Eli Lilly is the more volatile: beta 0.39 against 0.37 for Novo Nordisk.
Competitors
Other companies investors compare Eli Lilly and Novo Nordisk with: AbbVie, Abbott, Vertex, Boston Scientific. AbbVie · Abbott · Vertex · Boston Scientific
How Eli Lilly and Novo Nordisk make money
Eli Lilly (LLY)
Eli Lilly sells prescription medicines. Its largest revenue source is tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, followed by Verzenio for breast cancer, Jardiance and Trulicity for diabetes, Taltz for immunology and Kisunla for Alzheimer's disease. The United States is its biggest market. Full Eli Lilly analysis.
Novo Nordisk (NVO)
Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. The United States is its biggest market, ahead of Europe, China and the rest of the world. Its ADRs trade in New York. Full Novo Nordisk analysis.
Frequently asked questions: Eli Lilly vs Novo Nordisk
What is the difference between Eli Lilly and Novo Nordisk?
Eli Lilly sells prescription medicines. Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. Both are in healthcare and pharma. As of November 19, 2026: P/E 44.9 vs 10.0; net margin 32% vs 34% (Eli Lilly vs Novo Nordisk).
Is Eli Lilly or Novo Nordisk the better stock?
Choosing between Eli Lilly and Novo Nordisk depends on what you are looking for. Eli Lilly is growing faster right now, and Novo Nordisk trades on the lower P/E. Fintols does not tell you whether to buy Eli Lilly or Novo Nordisk: it shows you the differences so you can decide.
Which pays a higher dividend, Eli Lilly or Novo Nordisk?
As of November 19, 2026, Novo Nordisk yields 4.56% and Eli Lilly yields 0.50%. Also check how much of their profit Eli Lilly and Novo Nordisk pay out: if it is more than they earn, it cannot last.
Which is more expensive, Eli Lilly or Novo Nordisk?
On P/E, Eli Lilly (44.9x) is more expensive than Novo Nordisk (10.0x) as of November 19, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.
Which is more profitable, Eli Lilly or Novo Nordisk?
On net margin, Novo Nordisk (33.9%) keeps more of every 100 it sells than Eli Lilly (31.9%), as of November 19, 2026.
Which has more debt, Eli Lilly or Novo Nordisk?
As of November 19, 2026, Eli Lilly owes 1.0x its EBITDA and Novo Nordisk owes 0.5x its EBITDA (net debt over EBITDA).
Can I own both Eli Lilly and Novo Nordisk?
Yes. Many people spread their money across several companies, such as Eli Lilly and Novo Nordisk, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Eli Lilly or Novo Nordisk.
To go deeper: Does Eli Lilly pay a dividend? and Does Novo Nordisk pay a dividend?.
Related comparisons for Eli Lilly and Novo Nordisk
More companies like Eli Lilly and Novo Nordisk: healthcare and pharma stocks. Educational content about Eli Lilly and Novo Nordisk, not investment advice.
Full analyses: Eli Lilly and Novo Nordisk. Machine-readable summary: llms.txt.
Your first analysis is free with a free account, no card.
Your own analysis of Eli Lilly or Novo Nordisk.
Create a free account and run your first full analysis in a minute. No card needed.
- How it makes money
- Valuation scenarios
- What could go wrong
First full analysis free · No card